Northern Trust Corp Apellis Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 453,102 shares of APLS stock, worth $15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
453,102
Previous 462,218 1.97%
Holding current value
$15 Million
Previous $17.7 Million 26.3%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$28.84 - $41.15 $262,905 - $375,123
-9,116 Reduced 1.97%
453,102 $13.1 Million
Q2 2024

Aug 14, 2024
BUY
$38.07 - $59.71 $828,479 - $1.3 Million
21,762 Added 4.94%
462,218 $17.7 Million
Q1 2024

May 14, 2024
SELL
$55.39 - $72.47 $458,075 - $599,326
-8,270 Reduced 1.84%
440,456 $25.9 Million
Q4 2023

Feb 13, 2024
SELL
$37.14 - $64.82 $63,286 - $110,453
-1,704 Reduced 0.38%
448,726 $26.9 Million
Q3 2023

Nov 13, 2023
SELL
$23.65 - $89.22 $9.5 Million - $35.9 Million
-401,842 Reduced 47.15%
450,430 $17.1 Million
Q2 2023

Aug 11, 2023
SELL
$76.68 - $93.31 $1.3 Million - $1.58 Million
-16,916 Reduced 1.95%
852,272 $77.6 Million
Q1 2023

May 15, 2023
BUY
$46.59 - $66.96 $562,201 - $808,006
12,067 Added 1.41%
869,188 $57.3 Million
Q4 2022

Feb 13, 2023
BUY
$43.24 - $61.04 $343,022 - $484,230
7,933 Added 0.93%
857,121 $44.3 Million
Q3 2022

Nov 14, 2022
BUY
$44.76 - $69.66 $738,092 - $1.15 Million
16,490 Added 1.98%
849,188 $58 Million
Q2 2022

Aug 12, 2022
BUY
$35.07 - $59.21 $2.37 Million - $4 Million
67,496 Added 8.82%
832,698 $37.7 Million
Q1 2022

May 13, 2022
BUY
$35.46 - $54.12 $756,539 - $1.15 Million
21,335 Added 2.87%
765,202 $38.9 Million
Q4 2021

Feb 08, 2022
BUY
$30.74 - $49.16 $2.5 Million - $3.99 Million
81,181 Added 12.25%
743,867 $35.2 Million
Q3 2021

Nov 15, 2021
SELL
$31.4 - $69.84 $370,865 - $824,880
-11,811 Reduced 1.75%
662,686 $21.8 Million
Q2 2021

Aug 13, 2021
BUY
$40.9 - $64.9 $416,075 - $660,227
10,173 Added 1.53%
674,497 $42.6 Million
Q1 2021

May 12, 2021
SELL
$40.8 - $57.39 $973,487 - $1.37 Million
-23,860 Reduced 3.47%
664,324 $28.5 Million
Q4 2020

Feb 11, 2021
SELL
$30.79 - $57.2 $553,481 - $1.03 Million
-17,976 Reduced 2.55%
688,184 $39.4 Million
Q3 2020

Nov 16, 2020
BUY
$25.89 - $33.65 $214,265 - $278,487
8,276 Added 1.19%
706,160 $21.3 Million
Q2 2020

Aug 14, 2020
BUY
$24.8 - $38.49 $322,772 - $500,947
13,015 Added 1.9%
697,884 $22.8 Million
Q1 2020

May 14, 2020
BUY
$17.91 - $44.33 $1.9 Million - $4.69 Million
105,867 Added 18.28%
684,869 $18.3 Million
Q4 2019

Feb 14, 2020
SELL
$22.1 - $30.8 $273,995 - $381,858
-12,398 Reduced 2.1%
579,002 $17.7 Million
Q3 2019

Nov 13, 2019
BUY
$24.09 - $32.18 $2.96 Million - $3.95 Million
122,868 Added 26.22%
591,400 $14.2 Million
Q2 2019

Aug 13, 2019
BUY
$18.0 - $25.34 $513,000 - $722,190
28,500 Added 6.48%
468,532 $11.9 Million
Q1 2019

May 13, 2019
BUY
$12.81 - $19.82 $55,134 - $85,305
4,304 Added 0.99%
440,032 $8.58 Million
Q4 2018

Feb 12, 2019
SELL
$11.47 - $18.71 $68,108 - $111,099
-5,938 Reduced 1.34%
435,728 $5.75 Million
Q3 2018

Nov 14, 2018
BUY
$16.57 - $21.03 $242,535 - $307,816
14,637 Added 3.43%
441,666 $7.85 Million
Q2 2018

Sep 18, 2018
BUY
$19.63 - $30.0 $423,890 - $647,820
21,594 Added 5.33%
427,029 $9.4 Million
Q2 2018

Aug 14, 2018
BUY
$19.63 - $30.0 $5.61 Million - $8.58 Million
285,992 Added 239.44%
405,435 $8.92 Million
Q1 2018

May 09, 2018
BUY
$14.01 - $26.02 $60,467 - $112,302
4,316 Added 3.75%
119,443 $2.64 Million
Q4 2017

Feb 14, 2018
BUY
$12.71 - $21.7 $1.46 Million - $2.5 Million
115,127
115,127 $2.5 Million

Others Institutions Holding APLS

# of Institutions
308
Shares Held
115M
Call Options Held
3.85M
Put Options Held
1.09M
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email